Spectrum.Life appoints former Bupa CMO as board director

Spectrum.Life has appointed Dr Paula Franklin as a director of the board.

Having trained in the UK and worked as a hospital doctor and a GP before studying Public Health at Johns Hopkins University in Baltimore, Dr Franklin (pictured) worked for the Children’s Defense Fund charity in Washington DC on US health policy and legislation.

Upon return to the UK in 1996, she joined Bupa where she held several senior medical roles, before eventually joining the senior leadership team as chief medical officer Bupa Group.

She is also on the board of the Youth Sport Trust in the UK and will serve as the chairwoman of Spectrum.Life’s Clinical Advisory Board.

Beyond her career in health, Dr Franklin is a leader in promoting inclusion and diversity, and served as the executive sponsor for Bupa’s global inclusion and diversity agenda.

As a trustee of the UK Bupa Foundation, she spearheaded initiatives supporting deprived communities and advocated for women and BAME colleagues in leadership.

Dr Franklin was named one of the 100 most influential people of African, African Caribbean, and African American heritage in the UK by the Powerlist for three consecutive years, which honours men and women across a range of industries including business, science, technology and the arts.

Dr Franklin said: “I feel privileged to become a director of Spectrum.Life.

“I find their approach to digital health and wellbeing incredibly inspiring, and I look forward to contributing to the next chapter of the company’s international growth and cementing its position as a leader and innovator in digital health solutions.

“Furthermore, I’m honoured to be chairing Spectrum.Life’s Clinical Advisory Board, helping the company to continue to lead the way in best class clinical standards.”

Stuart McGoldrick, founder and executive chairman of Spectrum.Life, added: “Paula is an excellent addition to our board. We are very excited about her joining us.

“I am delighted she has agreed to chair our Clinical Advisory Board, further solidifying our commitment to advancing high quality whole of health solutions.”

Exit mobile version